" /> 【連載・第2回】呼吸器内科医のための肺移植の診かた■肺移植施設への紹介と移植登録■平間 崇 |
呼吸臨床

【連載】呼吸器内科医のための肺移植の診かた/A guide to lung transplant for pulmonologists


第2回 肺移植施設への紹介と移植登録


平間 崇*,**


*東北大学加齢医学研究所呼吸器外科学分野(〒980-8575宮城県仙台市青葉区星陵町4-1)

**東北大学病院臓器移植医療部


Referral and listing for lung transplant in Japan


Takashi Hirama*,**


*Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

**Division of Organ Transplantation, Tohoku University Hospital


Keywords:肺移植,紹介,移植適応,移植登録,予防接種,呼吸器内科/lung transplant, referral, transplant indication, listing, vaccination, pulmonologist


呼吸臨床 2022年6巻8号 論文No.e00155
Jpn Open J Respir Med 2022 Vol. 6 No. 8 Article No.e00155

DOI: 10.24557/kokyurinsho.6.e00155


掲載日:2022年8月19日


©️Takashi Hirama. 本論文の複製権,翻訳権,上映権,譲渡権,貸与権,公衆送信権(送信可能化権を含む)は弊社に帰属し,それらの利用ならびに許諾等の管理は弊社が行います。





要旨

 呼吸器内科医は,患者にとって肺移植が治療の選択肢となり得ると考えた場合,まず肺移植実施施設(移植施設)へ相談または紹介する。移植登録のためには,肺移植インフォームド・コンセントに加え,肺移植を実施する診療科での検討会,地区肺移植適応検討委員会,中央肺移植適応検討委員会,と3段階での評価が必要となる。そこで承認をされた後,日本臓器移植ネットワークへ登録となる。本稿では,移植施設への紹介から日本臓器移植ネットワークへの登録,さらに移植待機中の対応について説明する。


文献

  1. Al-Adra DP, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021; 21: 475–83. doi:10.1111/ajt.16324.
  2. Al-Adra DP, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021; 21: 460–74. doi: 10.1111/ajt.16318.
  3. Hirama T, et al. Outcomes of a peri- and postoperative management protocol for non-TB mycobacteria in lung transplant recipients. Chest. 2020; 158: 523–8. doi: 10.1016/j.chest.2020.01.056.
  4. Hirama T, et al. Outcome and prognostic factors after lung transplantation for bronchiectasis other than cystic fibrosis. BMC Pulm Med. 2021; 21: 261. doi: 10.1186/s12890-021-01634-z.
  5. Aguado JM, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2018; 32: 36–57. doi: 10.1016/j.trre.2017.07.001.
  6. Galiè N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endor. Eur Heart J. 2016; 37: 67–119. doi: 10.1093/eurheartj/ehv317.
  7. Hirama T, et al. Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study. BMC Pulm Med. 2021; 21: 1–9. doi: 10.1186/s12890-021-01760-8.
  8. Crespo MM, et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. J Heart Lung Transplant. 2021; 40: 1251–66. doi: 10.1016/j.healun.2021.07.014.
  9. Bermudez CA, et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. J Heart Lung Transplant. 2021; 40: 1267–78. doi: 10.1016/j.healun.2021.07.016.
  10. Coker RK, et al. BTS Clinical Statement on air travel for passengers with respiratory disease. Thorax 2022; 77:329–50. doi: 10.1136/thoraxjnl-2021-218110.
  11. 日本移植学会成人臓器移植予防接種ガイドライン策定委員会. 成人臓器移植予防接種ガイドライン. 東京: メディカルレビュー社, 2018.
  12. Hirama T, et al. Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients. J Infect Chemother 2022. doi: 10.1016/j.jiac.2022.04.019.